COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022
Irina Kislaya, Ausenda Machado, Sarah Magalhães, Ana Paula Rodrigues, Rafael Franco, Pedro Pinto Leite, Carlos Matias Dias, Baltazar Nunes
Abstract
We measured vaccine effectiveness (VE) against COVID-19-related severe outcomes in elderly people in Portugal between May and July 2022. In ≥ 80 year-olds, the second booster dose VE was 81% (95% CI: 75-85) and 82% (95% CI: 77-85), respectively, against COVID-19-related hospitalisation and death. The first booster dose VE was 63% (95% CI: 55-70) in ≥ 80 year-olds and 74% (95% CI: 66-80) in 60-79 year-olds against hospitalisation, and 63% (95% CI: 57-69) and 65% (95% CI: 54-74) against death.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Booster (rocketry)Health recordsVirologyElectronic health recordCohortMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Circulation (fluid dynamics)Internal medicinePhysicsInfectious disease (medical specialty)Health careDiseaseEconomic growthEconomicsThermodynamicsAstronomySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19